Measure: CMS153
Chlamydia Screening for Women
Measure Versions
| eMeasure Code |
Measure Year |
Full Version Number |
Title |
| CMS153v12 |
2024 |
12.0.000 |
Chlamydia Screening in Women |
| CMS153v11 |
2023 |
11 |
Chlamydia Screening for Women |
| CMS153v10 |
2022 |
10.0.000 |
Chlamydia Screening for Women |
| CMS153v9 |
2021 |
9.2.000 |
Chlamydia Screening for Women |
| CMS153v8 |
2020 |
8.1.000 |
Chlamydia Screening for Women |
| CMS153v7 |
2019 |
7.4.000 |
Chlamydia Screening for Women |
| CMS153v6 |
2018 |
6.2.000 |
Chlamydia Screening for Women |
| CMS153v5 |
2017 |
5.0.000 |
Chlamydia Screening for Women |
Description
Percentage of women 16-24 years of age who were identified as sexually active and who had at least one test for chlamydia during the measurement period
Guidance
Codes to identify sexually active women include codes for: pregnancy, sexually transmitted infections, contraceptives or contraceptive devices, and infertility treatments.
The denominator exclusion does not apply to patients who qualify for the initial population (IP) based on services other than the pregnancy test alone. These other services include services for sexually transmitted infections, contraceptives or contraceptive devices and infertility treatments. For example, a patient who has both a pregnancy test and a chlamydia diagnosis, either of which would qualify them for the IP, would not be eligible for this denominator exclusion.
Patient Group Definitions
| Group |
Description |
Instructions Links |
| Initial Population | Women 16 to 24 years of age who are sexually active and who had a visit in the measurement period | Webchart Instructions |
| Denominator | Equals Initial Population | Webchart Instructions |
| Denominator Exclusions | Women who are only eligible for the initial population due to a pregnancy test and who had an x-ray or an order for a specified medication within 7 days of the pregnancy test | Webchart Instructions |
| Numerator | Women with at least one chlamydia test during the measurement period | Webchart Instructions |
| Numerator Exclusions | Not Applicable | Webchart Instructions |
| Denominator Exceptions | None | |
Details
| Full eMeasure Code |
eMeasure Identifier |
Measure Year |
Version |
NQF # |
GUID |
| CMS153v5 |
153 |
2017 |
5.0.000 |
0033 |
c9930664-be3d-4ffe-ae4a-5cf4933ecb89 |
| Steward |
Developer |
Endorsed By |
| National Committee for Quality Assurance |
National Committee for Quality Assurance |
National Quality Forum |
| Scoring Method |
Measure Type |
Stratification |
Risk Adjustment |
| Proportion |
PROCESS |
Report a total score, and each of the following strata:
Stratum 1: Patients age 16-20
Stratum 2: Patients age 21-24 |
None |
Rate Aggregation
None
Improvement Notation
Higher score indicates better quality
Rationale
Chlamydia trachomatis is the most common sexually transmitted bacterial infection in the U.S., resulting in over 1.4 million cases each year (USPSTF 2014, CDC 2014). Chlamydia infections are often asymptomatic, but, if left untreated, can lead to serious and irreversible complications (USPSTF 2014, CDC 2014).
Women are particularly vulnerable when infected with chlamydia. Left untreated, chlamydia can cause pelvic inflammatory disease (PID), which can lead to chronic pelvic pain or infertility. Pregnant women may also transmit the infection to their infant, potentially resulting in neonatal pneumonia (CDC 2014).
Clinical Recommendation Statement
U.S. Preventive Services Task Force (USPSTF) (2014):
The USPSTF recommends screening for chlamydia in sexually active females aged 24 years or younger and in older women who are at increased risk for infection. (B recommendation)
Definition
None
Transmission Format
TBD
Applicable Value Sets
| Category |
Value Set |
OID |
| Diagnosis |
Chlamydia |
2.16.840.1.113883.3.464.1003.112.12.1003 |
| Diagnosis |
Complications of Pregnancy, Childbirth and the Puerperium |
2.16.840.1.113883.3.464.1003.111.12.1012 |
| Diagnosis |
Genital Herpes |
2.16.840.1.113883.3.464.1003.110.12.1049 |
| Diagnosis |
Gonococcal Infections and Venereal Diseases |
2.16.840.1.113883.3.464.1003.112.12.1001 |
| Diagnosis |
HIV |
2.16.840.1.113883.3.464.1003.120.12.1003 |
| Diagnosis |
Inflammatory Diseases of Female Reproductive Organs |
2.16.840.1.113883.3.464.1003.112.12.1004 |
| Diagnosis |
Other Female Reproductive Conditions |
2.16.840.1.113883.3.464.1003.111.12.1006 |
| Diagnosis |
Syphilis |
2.16.840.1.113883.3.464.1003.112.12.1002 |
| Diagnostic Study, Order |
Diagnostic Studies During Pregnancy |
2.16.840.1.113883.3.464.1003.111.12.1008 |
| Diagnostic Study, Order |
X-Ray Study (all inclusive) |
2.16.840.1.113883.3.464.1003.198.12.1034 |
| Encounter, Performed |
Face-to-Face Interaction |
2.16.840.1.113883.3.464.1003.101.12.1048 |
| Encounter, Performed |
Home Healthcare Services |
2.16.840.1.113883.3.464.1003.101.12.1016 |
| Encounter, Performed |
Office Visit |
2.16.840.1.113883.3.464.1003.101.12.1001 |
| Encounter, Performed |
Preventive Care - Established Office Visit, 0 to 17 |
2.16.840.1.113883.3.464.1003.101.12.1024 |
| Encounter, Performed |
Preventive Care Services - Established Office Visit, 18 and Up |
2.16.840.1.113883.3.464.1003.101.12.1025 |
| Encounter, Performed |
Preventive Care Services-Initial Office Visit, 18 and Up |
2.16.840.1.113883.3.464.1003.101.12.1023 |
| Encounter, Performed |
Preventive Care- Initial Office Visit, 0 to 17 |
2.16.840.1.113883.3.464.1003.101.12.1022 |
| Laboratory Test, Order |
Lab Tests During Pregnancy |
2.16.840.1.113883.3.464.1003.111.12.1007 |
| Laboratory Test, Order |
Lab Tests for Sexually Transmitted Infections |
2.16.840.1.113883.3.464.1003.110.12.1051 |
| Laboratory Test, Order |
Pap Test |
2.16.840.1.113883.3.464.1003.108.12.1017 |
| Laboratory Test, Order |
Pregnancy Test |
2.16.840.1.113883.3.464.1003.111.12.1011 |
| Laboratory Test, Performed |
Chlamydia Screening |
2.16.840.1.113883.3.464.1003.110.12.1052 |
| Medication, Active |
Contraceptive Medications |
2.16.840.1.113883.3.464.1003.196.12.1080 |
| Medication, Order |
Contraceptive Medications |
2.16.840.1.113883.3.464.1003.196.12.1080 |
| Medication, Order |
Isotretinoin |
2.16.840.1.113883.3.464.1003.196.12.1143 |
| Patient Characteristic Ethnicity |
Ethnicity |
2.16.840.1.114222.4.11.837 |
| Patient Characteristic Payer |
Payer |
2.16.840.1.114222.4.11.3591 |
| Patient Characteristic Race |
Race |
2.16.840.1.114222.4.11.836 |
| Patient Characteristic Sex |
Female |
2.16.840.1.113883.3.560.100.2 |
| Patient Characteristic Sex |
ONC Administrative Sex |
2.16.840.1.113762.1.4.1 |
| Procedure, Performed |
Delivery Live Births |
2.16.840.1.113883.3.464.1003.111.12.1015 |
| Procedure, Performed |
Procedures During Pregnancy |
2.16.840.1.113883.3.464.1003.111.12.1009 |
| Procedure, Performed |
Procedures Involving Contraceptive Devices |
2.16.840.1.113883.3.464.1003.111.12.1010 |
References
Centers for Disease Control and Prevention (CDC). 2014. "Sexually Transmitted Disease Surveillance 2013." Atlanta, GA.
U.S. Preventive Services Task Force (USPSTF). 2014. "Screening for Chlamydia and Gonorrhea: U.S. Preventive Services Task Force Recommendation Statement." Ann Intern Med 161:902-910.
Disclaimer
These performance Measures are not clinical guidelines and do not establish a standard of medical care, and have not been tested for all potential applications.
THE MEASURES AND SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND.
Due to technical limitations, registered trademarks are indicated by (R) or [R] and unregistered trademarks are indicated by (TM) or [TM].
Copyright
Physician Performance Measure (Measures) and related data specifications were developed by the National Committee for Quality Assurance (NCQA).
The Measures are copyrighted but can be reproduced and distributed, without modification, for noncommercial purposes (eg, use by healthcare providers in connection with their practices). Commercial use is defined as the sale, licensing, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial use of the Measures requires a license agreement between the user and NCQA. NCQA is not responsible for any use of the Measures.
(c) 2008-2016 National Committee for Quality Assurance. All Rights Reserved.
Limited proprietary coding is contained in the Measure specifications for user convenience. Users of proprietary code sets should obtain all necessary licenses from the owners of the code sets. NCQA disclaims all liability for use or accuracy of any CPT or other codes contained in the specifications.
CPT(R) contained in the Measure specifications is copyright 2004-2015 American Medical Association. LOINC(R) copyright 2004-2015 Regenstrief Institute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED CT[R]) copyright 2004-2015 International Health Terminology Standards Development Organisation. ICD-10 copyright 2015 World Health Organization. All Rights Reserved.
Source:
https://ecqi.healthit.gov/ecqm/measures/cms153v5